HK1027039A1 - Pharmaceutical composition comprising 2-amino-2-[2-(4- octylphenyl)ethyl]propane-1,3-diol, a lecithin and a saccharidee - Google Patents

Pharmaceutical composition comprising 2-amino-2-[2-(4- octylphenyl)ethyl]propane-1,3-diol, a lecithin and a saccharidee

Info

Publication number
HK1027039A1
HK1027039A1 HK00106244.1A HK00106244A HK1027039A1 HK 1027039 A1 HK1027039 A1 HK 1027039A1 HK 00106244 A HK00106244 A HK 00106244A HK 1027039 A1 HK1027039 A1 HK 1027039A1
Authority
HK
Hong Kong
Prior art keywords
octylphenyl
lecithin
diol
propane
ethyl
Prior art date
Application number
HK00106244.1A
Other languages
English (en)
Inventor
Atsushi Sakai
Rumiko Masuda
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1027039A1 publication Critical patent/HK1027039A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK00106244.1A 1997-02-27 2000-09-29 Pharmaceutical composition comprising 2-amino-2-[2-(4- octylphenyl)ethyl]propane-1,3-diol, a lecithin and a saccharidee HK1027039A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP4366897 1997-02-27
PCT/JP1998/000755 WO1998037875A1 (fr) 1997-02-27 1998-02-25 Composition medicamenteuse

Publications (1)

Publication Number Publication Date
HK1027039A1 true HK1027039A1 (en) 2001-01-05

Family

ID=12670236

Family Applications (2)

Application Number Title Priority Date Filing Date
HK00106244.1A HK1027039A1 (en) 1997-02-27 2000-09-29 Pharmaceutical composition comprising 2-amino-2-[2-(4- octylphenyl)ethyl]propane-1,3-diol, a lecithin and a saccharidee
HK00107199A HK1027959A1 (en) 1997-02-27 2000-11-10 Drug composition.

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK00107199A HK1027959A1 (en) 1997-02-27 2000-11-10 Drug composition.

Country Status (19)

Country Link
US (1) US6277888B1 (es)
EP (2) EP2030614A1 (es)
JP (1) JP4153563B2 (es)
KR (1) KR20000075745A (es)
CN (1) CN1178653C (es)
AT (1) ATE412407T1 (es)
AU (1) AU735406B2 (es)
BR (1) BR9811453A (es)
CA (1) CA2282378C (es)
DE (1) DE69840169D1 (es)
DK (1) DK0990440T3 (es)
ES (1) ES2317663T3 (es)
HK (2) HK1027039A1 (es)
IL (1) IL131608A (es)
NZ (1) NZ337823A (es)
PT (1) PT990440E (es)
RU (1) RU2188004C2 (es)
SI (1) SI0990440T1 (es)
WO (1) WO1998037875A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624038D0 (en) * 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
JP4627356B2 (ja) 1999-06-30 2011-02-09 松森　　昭 ウイルス性心筋炎の予防または治療薬剤
AU2001285331B2 (en) 2000-08-31 2006-04-06 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents
PT1471054E (pt) 2002-01-11 2009-09-23 Daiichi Sankyo Co Ltd Derivado de aminoálcool ou derivado de ácido fosfónico e composição medicinal que os contém
PE20130200A1 (es) * 2003-04-08 2013-03-09 Novartis Ag Composicion farmaceutica que contiene un agonista del receptor s1p y un alcohol de azucar
GB0329498D0 (en) * 2003-12-19 2004-01-28 Novartis Ag Organic compounds
KR20110136901A (ko) 2004-02-24 2011-12-21 상꾜 가부시키가이샤 아미노 알코올 화합물
AU2005266449B2 (en) * 2004-07-30 2009-10-08 Novartis Ag Compound formulations of 2-amino-1,3-propanediol compounds
MX2007006373A (es) * 2004-11-29 2007-06-20 Novartis Ag Regimen de dosificacion de un agonista del receptor s1p.
EP1679065A1 (en) 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Controlled release compositions for interferon based on PEGT/PBT block copolymers
MX2008003170A (es) * 2005-09-09 2008-03-18 Novartis Ag Tratamiento de enfermedades autoinmunes.
EP1923055A1 (en) * 2006-09-26 2008-05-21 Novartis AG Freeze-dried pharmaceutical composition comprising an S1P agonist or modulator
AU2011235934A1 (en) * 2006-09-26 2011-11-03 Novartis Ag Pharmaceutical compositions comprising an S1P modulator
WO2009048993A2 (en) 2007-10-12 2009-04-16 Novartis Ag Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators
KR101718639B1 (ko) 2008-03-17 2017-03-21 액테리온 파마슈티칼 리미티드 선별적 ｓ1ｐ₁ 수용체 작동약에 대한 투약 섭생
JO3177B1 (ar) 2011-04-01 2018-03-08 Novartis Ag تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول
RU2483749C2 (ru) * 2011-04-15 2013-06-10 Леонид Леонидович Клопотенко Фармацевтическая композиция, содержащая инсулин и липосомы, для местного применения в виде биопленки
RU2483748C2 (ru) * 2011-04-15 2013-06-10 Леонид Леонидович Клопотенко Фармацевтическая композиция, содержащая инсулин и липосомы, для местного применения в виде пластыря
MX364643B (es) * 2011-08-03 2019-05-03 Ma Zhongmin USO DEL COMPUESTO FTY720: 2-amino - 2-[2-(4-octilfenil) etil] propano-1,3-diol (fingolimod) EN EL TRATAMIENTO DE PACIENTES CON DIABETES DE TIPO 2.
MX2016001422A (es) * 2013-07-29 2016-10-05 Aizant Drug Res Solutions Pvt Ltd Composicion farmaceutica de fingolimod.
GR1009654B (el) 2018-08-31 2019-11-18 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει εναν ανοσοτροποποιητικο παραγοντα και μεθοδος για την παρασκευη αυτου

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5612993B2 (es) 1973-09-03 1981-03-25
US4020159A (en) * 1974-10-08 1977-04-26 Apotheker A. Herbert K.G., Fabrik Pharmazeutischer Praparate Wiesbaden Methods of and medications for treating cardiac disorders by using strophanthin
JPS5562010A (en) 1978-10-31 1980-05-10 Ajinomoto Co Inc Fat emulsion for intravenous injection
AU5078885A (en) * 1984-12-20 1986-06-26 Warner-Lambert Company Non-irritant detergent
JPS61172814A (ja) * 1985-01-25 1986-08-04 Ss Pharmaceut Co Ltd 安定な低溶血性ビタミンｅ注射液
JPS63152327A (ja) * 1987-11-20 1988-06-24 Toyama Chem Co Ltd 脂肪乳剤から成る溶血防止用組成物を含有する製剤
JPH01172814A (ja) 1987-12-26 1989-07-07 Canon Inc レーザーユニット
AU6461090A (en) 1989-10-30 1991-05-02 Abbott Laboratories Injectable formulation for lipophilic drugs
US5091188A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
JPH04173736A (ja) * 1990-11-06 1992-06-22 Nippon Shinyaku Co Ltd 乳化剤
DE122011100012I1 (de) 1992-10-21 2011-10-20 Mitsubishi Tanabe Pharma Corp 2-Amino-1, 3-propandiolverbindung und immunosuppressium.
JPH06340525A (ja) 1993-06-02 1994-12-13 Lion Corp 安定な低眼刺激性ビタミンａ類可溶化点眼剤
DE69524962T4 (de) * 1994-08-22 2003-08-28 Mitsubishi Pharma Corp., Osaka Benzolderivate und deren medizinische verwendung
JP3169807B2 (ja) 1995-09-18 2001-05-28 本田技研工業株式会社 ロータ組み付け装置
HU224814B1 (en) * 1995-12-28 2006-02-28 Mitsubishi Pharma Corp Use of propane-1,3-diol derivative for the preparation of a medicament useful for the topical treating of inflammatory and immune diseases
JP2002241272A (ja) * 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
KR100190826B1 (ko) * 1996-08-26 1999-06-01 강재헌 적혈구 용혈 억제용 약제학적 조성물 및 그의제조방법

Also Published As

Publication number Publication date
CN1178653C (zh) 2004-12-08
US6277888B1 (en) 2001-08-21
DK0990440T3 (da) 2009-02-23
EP0990440A4 (en) 2004-04-21
PT990440E (pt) 2009-02-05
SI0990440T1 (sl) 2009-04-30
EP0990440A1 (en) 2000-04-05
WO1998037875A1 (fr) 1998-09-03
EP2030614A1 (en) 2009-03-04
RU2188004C2 (ru) 2002-08-27
CN1253499A (zh) 2000-05-17
BR9811453A (pt) 2000-09-12
JP4153563B2 (ja) 2008-09-24
AU6115598A (en) 1998-09-18
EP0990440B1 (en) 2008-10-29
NZ337823A (en) 2001-04-27
CA2282378A1 (en) 1998-09-03
ES2317663T3 (es) 2009-04-16
IL131608A (en) 2003-02-12
HK1027959A1 (en) 2001-02-02
DE69840169D1 (de) 2008-12-11
ATE412407T1 (de) 2008-11-15
CA2282378C (en) 2008-12-30
AU735406B2 (en) 2001-07-05
KR20000075745A (ko) 2000-12-26
IL131608A0 (en) 2001-01-28

Similar Documents

Publication Publication Date Title
HK1027039A1 (en) Pharmaceutical composition comprising 2-amino-2-[2-(4- octylphenyl)ethyl]propane-1,3-diol, a lecithin and a saccharidee
PT1050301E (pt) Composições medicinais contendo 2-amino-2-[2-(4- octilfenil)etil]propano-1,3-diol
AU1172997A (en) 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol or a pharmaceutically acceptable acid addition salt thereof for use in the preparation of a non-oral medicament, and for treatment of diseases and disorders
HUP0000558A3 (en) Use of active d vitamin analogues for producing pharmaceutical composition for the treatment of prostatic diseases
DE59902055D1 (de) Zweiteilige kapsel zur aufnahme von pharmazeutischen zubereitungen für pulverinhalatoren
UY23665A1 (es) Procedimiento para la preparacion de compuesto farmaceutico
NO166448C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tiazolidindioner.
CA2229282A1 (en) Use of hyaluronic acid as an immunosuppressant
RU99120398A (ru) Фармацевтическая композиция
ITRM940570A0 (it) "sale della l-carnitina e composizioni farmaceutiche che lo contengonoper il trattamento di affezioni cutanee"
HUP0202525A2 (hu) Mofetil mikofenolát és PEG-IFN-alfa együttes alkalmazása, valamint az azokat tartalmazó gyógyszerkészítmények és kit
BR9814053A (pt) Diésteres lipofìlicos de agentes de quelação
BR9810452A (pt) Nova combinação de medicamentos contra asma
ITRM940571A0 (it) "sale della l-carnitina e composizioni farmaceutiche che lo contengonoper il trattamento di affezioni cutanee"
AU2002366774A1 (en) A process for preparing n-acylated lysophosphatidylcholine and a pharmaceutical composition for treatment of metabolic bone disease comprising said compounds
GB2008403A (en) Peptide Compositions
EP0743068A3 (en) Composition for inhibiting bone loss containing vanadyl sulfate
NO20001895D0 (no) Anvendelse av glykosaminoglykaner for fremstilling av farmasøytiske preparater for behandling av diabetes assosierte- øyesykdommer
DK0704219T3 (da) Anvendelse af faktor for osteoblastisk celledeling
AU2506188A (en) Azelastine embonate, processes for its preparation and pharmaceutical formulations which contain azelastine embonate as active substance
ATE134135T1 (de) Ein imidazobenzodiazepin zur behandlung von schlafstörungen
TH25306A (th) วิธีของการใช้สำหรับยับยั้งการสูญเสียกระดูกและการลดคอเลสเทอรอลในซีรัม
TH25306B (th) วิธีของการใช้สำหรับยับยั้งการสูญเสียกระดูกและการลดคอเลสเทอรอลในซีรัม
SE9002435D0 (sv) Medel samt foerfarande foer behandling av biologisk implantationsvaevnad
IL145297A0 (en) Use of an agent for the manufacture of a medicament for the treatment of bone diseases

Legal Events

Date Code Title Description
CORR Corrigendum

Free format text: CORRECTED DATA OF SECTION 20 TO JOURNAL OF : [54] PHARMACEUTICAL COMPOSITION COMPRISING 2-AMINO-2-[2-(4- - OCTYLPHENYL)ETHYL]PROPANE-1,3-DIOL, A LECITHIN AND A SACCHARIDE

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)